Working together to treat rare disease
Odylia Therapeutics is a 501(c)(3) corporation combining the expertise and experience of our founders, board members, and partner organizations to fill a unique void in moving ultra-rare inherited retinal diseases from science to humans. Our organization focuses on those diseases that would typically have limited commercial appeal and would be neglected, even though the science is available to make significant progress.
Board of Directors
Khandan Baradaran, PhD
Vice President and Global Head of Regulatory CMC, Ultragenyx Pharmaceuticals
Scott Dorfman, BBA
Cofounder & Chairman of the Board, Odylia Therapeutics
Brian Fenton
President & CEO, Photys Therapeutics
Mat Pletcher, PhD
CSO, Kisbee Therapeutics
Founder, RDH12 Fund for Sight
Gregory Robinson, PhD
Chief Scientific Officer, Tevard Biosciences
Luk Vandenberghe, PhD
Cofounder, Odylia Therapeutics
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear
Scientific Advisory Board
Tiansen Li, PhD
Senior Investigator, Retinal Cell Biology and Degeneration Section, NEI
Joy Cavagnaro, PhD
President, Access Bio
Jean Bennett, MD, PhD
Professor, Perelman School of Medicine
University of Pennsylvania
Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear
Alan Spiro, BA, PhD, JD
Partner, ExSight Ventures
Founding Members
Luk Vandenberghe, PhD
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear
Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear
Scott Dorfman, BBA
CEO, Odylia Therapeutics
John Fernandez, MS
President and CEO,
Massachusetts Eye and Ear
Joan Miller, MD
Chief of Ophthalmology,
Massachusetts Eye and Ear